Northern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)

Northern Trust Corp purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 143,721 shares of the company’s stock, valued at approximately $2,363,000. Northern Trust Corp owned about 0.27% of Upstream Bio at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in UPB. FMR LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $117,977,000. Decheng Capital LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $54,010,000. Bain Capital Life Sciences Investors LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $37,735,000. Wellington Management Group LLP bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $25,632,000. Finally, Alliancebernstein L.P. bought a new position in Upstream Bio during the 4th quarter worth $18,270,000.

Upstream Bio Stock Performance

Shares of UPB opened at $9.16 on Monday. The stock has a fifty day moving average price of $8.04 and a 200 day moving average price of $12.26. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.71 million. On average, equities analysts forecast that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.